Currently available ocular drug-delivery systems in clinical trials for the treatment of anterior segment disorders (Kang-Mieler et al., 2014)
| Drug | Brand Name | Mode of Administration | Excipient Controlling Release Characteristic of Drug | Target Indication | Developmental Stage | Clinical Trial # |
|---|---|---|---|---|---|---|
| Azithromycin | AzaSite (Akorn, Inc.) | Eye drops | Polycarbophil (DuraSite) | Bacterial conjunctivitis | Launched | NCT00105469 |
| Azithromycin/dexamethasone (ISV-502) | AzaSite Plus (Akorn Inc.) | Eye drops | Polycarbophil (DuraSite) | Blepharoconjuntivitis | Launched | NCT00578955 |
| Betaxolol | Betoptic S (Novartis pharmaceuticals) | Eye drops | Glaucoma | Launched | NCT00061542 | |
| Bimatoprost | Lumigan (Allergan) | Eye drops | Glaucoma | Launched | NCT01589510 | |
| Bromfenac | Prolensa (Bausch & Lomb) | Eye drops | Postoperative inflammation | Launched | NCT01847638 | |
| Cyclosporine-A | Restasis (Allergan Inc.) | Eye drops | Cationic emulsion | Dry eye due to keratitis sicca | Launched | NCT02554981 |
| Difluprednate | Durezol (Novartis Pharmaceuticals) | Eye drops | Emulsion | Anterior uveitis | Launched | NCT01201798 |
| Timolol maleate | Timoptic (Bausch & Lomb) | Eye drops | Glaucoma/intraocular hypertension | Launched | ||
| Tobramycin/dexamethasone | TobraDex ST (Novartis Pharmaceuticals) | Eye drops | Xanthan gum | Blepharitis | Launched | NCT01102244 |
| Timolol maleate | Timoptic-XE (Merck & Co., Inc) | Eye drops | Gellan gum | Glaucoma | Launched | NCT01446497 |
| Ophthalmic emulsion | Cationorm (Santen Pharmaceuticals) | Eye drops | Cationic emulsion | Mild dry eye | NCT03460548 | |
| Travoprost | iStent Inject (Glaukos Healthcare) | Punctum plug | Open-angle glaucoma | Phase IV | NCT03624699 | |
| Cyclosporine (LX201) | Episcleral implant | Silicone | Keratoconjuntivitis | Phase III | NCT00447642 | |
| Dexamethasone phosphate (EGP-437) | EyeGate II (Eye Gate Pharma) | Iontophoresis | Anterior uveitis | Phase III | NCT01129856 | |
| Dexamethasone (OTX-DP) | Punctum plug | Hydrogel | Postoperative inflammation | Phase II | NCT00650702 | |
| Latanoprost | Durasert (pSivida Corp.) | Subconjunctival insert | PLGA | Glaucoma | Phase I/II | NCT00224289 |
| Loteprednol etabonate mucus-penetrating particles | Inveltys (Kala Pharmaceuticals, Inc) | Nanoparticle | Mucus-penetrating particles | Kerato conjunctivitis sicca | Phase III | NCT03616899 |
| Urea | Nanoparticle | Amphiphilic block copolymer PluronicF-127 | Cataract | Phase II | NCT03001466 | |
| Omega-3 fatty acids | Remogen Omega (TRB Chemedica) | Microparticle | Microemulsion of polyunsaturated fatty acids and hydrating polymers | Dry eye disease | Phase I/II | NCT02908282 |